Ibtrozi in Pakistan

How patients in Pakistan access Ibtrozi (BTK inhibitor class) via Named Patient Program.

Ibtrozi - overview

Ibtrozi (BTK inhibitor class) is manufactured by TBD – verify (BeiGene/Pharmacyclics?) and indicated for B-cell malignancies – confirm. It is a ROS1 TKI approved by the US FDA in 2025 and may be accessible to patients in Pakistan through a Named Patient Program or personal-import pathway.

Access in Pakistan

Pakistan's DRAP permits personal-use import of unregistered specialty drugs; documentation-heavy process.

How Reserve Meds coordinates access in Pakistan

  1. Patient or treating physician submits a request.
  2. We verify clinical appropriateness and Pakistan-specific eligibility.
  3. Treating physician in Pakistan issues prescription and clinical justification.
  4. Country-specific NPP/personal-import forms are prepared and filed.
  5. We source Ibtrozi from a DSCSA-compliant US specialty wholesaler.
  6. Cold-chain shipment to the patient's physician or hospital pharmacy in Pakistan.

Typical timeline for Pakistan

End-to-end, most requests are completed in 2-6 weeks. Pakistan's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Pakistan ask

  • Is the pathway legal in Pakistan? Yes - it operates under Pakistan's established NPP or personal-import framework.
  • Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
  • What physician credentials do I need? A licensed physician in Pakistan able to issue the prescription and clinical justification.
  • What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
  • Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Ibtrozi in Pakistan

Request Ibtrozi

GREEN
AI Regulatory Review Agent — preliminary signal
Small-molecule specialty therapy with clear personal import pathway in Pakistan via DRAP. Oral delivery; standard logistics.
Rule: sm_specialty_clear_pathway • Reviewed 2026-04-22

Start an intake request

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (dispensed by Altima Care, US-licensed specialty pharmacy) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp